최소 단어 이상 선택하여야 합니다.
최대 10 단어까지만 선택 가능합니다.
다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기Archives of pharmacal research : a publication of the Pharmaceutical Society of Korea, v.31 no.8, 2008년, pp.1055 - 1059
Piao, Zong-Zhu (National Research Lab. for Bioavailability Control, College of Pharmacy, Kangwon National University) , Lee, Eung-Seok (National Research Lab. for Bioavailability Control, College of Pharmacy, Kangwon National University) , Tran, Huyen Thi Thanh (National Research Lab. for Bioavailability Control, College of Pharmacy, Kangwon National University) , Lee, Beom-Jin (National Research Lab. for Bioavailability Control, College of Pharmacy, Kangwon National University)
The primary objective of the study was to validate a simple and sensitive method of determining valsartan concentration in human plasma samples using high performance liquid chromatography (HPLC) combined with ultraviolet (UV) detection. Methanol appeared to be the best with a high recovery efficien...
J. Incl. Phenom., Macrocycl. Chem. C. Brunella 54 289 2006 10.1007/s10847-005-9004-y Brunella, C., Clelia, D. M., Maria, I., and Agnese, M., Improvement of Solubility and Stability of valsartan by Hydroxypropyl-β-Cyclodextrin. J. Incl. Phenom., Macrocycl. Chem., 54, 289-294 (2006).
Eur. J. Clin. Pharmacol. C. Czendlik 52 451 1997 10.1007/s002280050318 Czendlik, C., Sioufi, A., Preiswerk, G., and Howald, H., Pharmacokinetic and pharmacodynamic interaction of single doses of valsartan and atenolol. Eur. J. Clin. Pharmacol., 52, 451-459 (1997).
J. Chromatogr. B. N. Daneshtalab 766 345 2002 10.1016/S0378-4347(01)00507-2 Daneshtalab, N., Lewanczuk, R. Z., and Jamali, F., High-performance liquid chromatographic analysis of angiotensin II receptor antagonist valsartan using a liquid extraction method. J. Chromatogr. B., 766, 345-349 (2002).
J. Chromatogr. N. Erk 784 195 2003 Erk, N., Simultaneous determination of irbesartan and hydrochlorothiazide in human plasma by liquid chromatography, J. Chromatogr., 784, 195-201 (2003).
Eur. J. Clin. Pharmacol. G. Flesch 52 115 1997 10.1007/s002280050259 Flesch, G., Müller, P., and Lioyd, P., Absolute bioavailability and pharmacokinetics of valsartan, an angiotensin II receptor antagonist, in man. Eur. J. Clin. Pharmacol., 52, 115-120 (1997).
J. Chromatogr. L. González A.949 49 2002 10.1016/S0021-9673(01)01496-0 González, L., López, J. A., Alonso, R. M., and Jiménez, R. M., Fast screening method for the determination of angiotensin II receptor antagonists in human plasma by high-performance liquid chromatography with fluorimetric detection. J. Chromatogr. A., 949, 49-60 (2002).
Guidance for industry: Bioanalytical method validation, U.S. Department of Health and Human Services, Food and Drug Administration. Centre for Drug Evaluation and Research (CDER), Centre for Veterinary Medicine (CVM). May 2001, http//www.fda.gov/cder/guidance/index.htm.
J. Pharm. Biomed. Anal. N. Koseki 43 1769 2007 10.1016/j.jpba.2006.12.030 Koseki, N., Kawashita, H., Hara, H., Niina, M., Tanaka, M., Kawai, R., Nagae, Y., and Masuda, N., Development and validation of a method for quantitative determination of valsartan in human plasma by liquid chromatography-tandem mass spectrometry. J. Pharm. Biomed. Anal., 43, 1769-1774 (2007).
J. Chromatogr. B. H. Li 852 436 2007 10.1016/j.jchromb.2007.02.014 Li, H., Wang, Y. G., Jiang, Y., Tang, Y. B., Wang, J., Zhao, L., and Gu, J. K., A liquid chromatography/tandem mass spectrometry method for the simultaneous quantification of valsartan and hydrochlorothiazide in human plasma. J. Chromatogr. B., 852, 436-442 (2007).
J. Chromatogr. B. J. Macek 832 169 2006 10.1016/j.jchromb.2005.12.035 Macek, J., Klima, J., and Ptáèek, P., Rapid determination of valsartan in human plasma by protein precipitation and high-performance liquid chromatography. J. Chromatogr. B., 832, 169-172 (2006).
Eur. J. Clin. Pharmacol. P. Müller 52 441 1997 10.1007/s002280050317 Müller, P., Flesch, G., Gasparo, M. D., Gasparini, M., and Howald, H., Pharmacokinetics and pharmacodynamic effects of the angiotensin II antagonist valsartan at steady state in healthy, normotensive subjects. Eur. J. Clin. Pharmacol., 52, 441-449 (1997).
Eur. J. Clin. Pharmacol. E. K. Schmidt 53 451 1998 10.1007/s002280050406 Schmidt, E. K., Antonin, K.-H., Flesch, G., and Racine, P.-A., An interaction study with cimetidine and the new angiotensin II antagonist valsartan. Eur. J. Clin. Pharmacol., 53, 451-458 (1998).
J. Pharm. Biomed. Anal. S. Tatar 30 371 2002 10.1016/S0731-7085(02)00360-6 Tatar, S. and Salk, S., Comparison of UV and second derivative-spectrophotometric and LC methods for the determination of valsartan in pharmaceutical formulation. J. Pharm. Biomed. Anal., 30, 371-375 (2002).
Xenobiotica F. Waldmeier 27 59 1997 10.1080/004982597240767 Waldmeier, F., Flesch, G., Müller, P., Winkler, T., Kriemler, H.P., Buhlmayer, P., and De Gaspro, M., Pharmacokinetics, disposition and biotransformation of [14C]-radiolabelled valsartan in healthy male volunteers after a single oral dose. Xenobiotica, 27, 59-71 (1997).
*원문 PDF 파일 및 링크정보가 존재하지 않을 경우 KISTI DDS 시스템에서 제공하는 원문복사서비스를 사용할 수 있습니다.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.